The Food and Drug Administration yesterday authorized the Novavax COVID-19 vaccine for emergency use in adults, as recommended last month by its vaccine advisory committee. If the Centers for Disease Control and Prevention also recommends the vaccine for adults, the protein-based vaccine would offer an option to individuals who may have an allergic reaction to or prefer not to receive an mRNA vaccine. The departments of Health and Human Services and Defense this month secured 3.2 million doses of the vaccine to give states, federal pharmacy partners and federally qualified health centers. The two-dose vaccine can be stored at 2-8 degrees Celsius (about 36-46 degrees Fahrenheit), enabling the use of existing vaccine supply and cold chain channels.
 

Related News Articles

Perspective
As we move into fall and winter, we know the viruses that cause respiratory disease will usually circulate more heavily in communities. Already, the Centers…
Headline
In these video snippets from an AHA Advancing Health podcast series, health care leaders and clinicians from four children's hospitals share how they worked to…
Headline
Most health insurers must cover the updated COVID-19 vaccines from Pfizer and Moderna without cost sharing effective Sept. 11, when the Food and Drug…
Headline
AHA today participated in a Centers for Disease Control and Prevention Fall Immunization Kick-off Event for partner organizations, which focused on vaccinating…
Headline
As authorized yesterday by the Food and Drug Administration and recommended by its vaccine advisory committee, the Centers for Disease Control and Prevention…
Headline
Under the Department of Health and Human Services’ recent agreement with Regeneron to develop a new monoclonal antibody to prevent COVID-19, the U.S. list…